DBV Technologies (DBVT) Competitors $10.30 -0.19 (-1.81%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$10.30 0.00 (0.00%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. COLL, AKBA, SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, and PRAXShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Its Competitors Collegium Pharmaceutical Akebia Therapeutics Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Ardelyx Oric Pharmaceuticals Praxis Precision Medicines Collegium Pharmaceutical (NASDAQ:COLL) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations. Which has more risk and volatility, COLL or DBVT? Collegium Pharmaceutical has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.59, indicating that its stock price is 159% less volatile than the S&P 500. Do analysts prefer COLL or DBVT? Collegium Pharmaceutical currently has a consensus price target of $43.75, suggesting a potential upside of 43.40%. DBV Technologies has a consensus price target of $14.75, suggesting a potential upside of 43.20%. Given Collegium Pharmaceutical's higher probable upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has higher valuation and earnings, COLL or DBVT? Collegium Pharmaceutical has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$631.45M1.55$69.19M$1.2225.01DBV Technologies$4.15M67.98-$113.92M-$4.92-2.09 Do institutionals and insiders hold more shares of COLL or DBVT? 71.7% of DBV Technologies shares are owned by institutional investors. 2.5% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 1.4% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is COLL or DBVT more profitable? Collegium Pharmaceutical has a net margin of 6.61% compared to DBV Technologies' net margin of -3,249.99%. Collegium Pharmaceutical's return on equity of 99.08% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical6.61% 99.08% 15.14% DBV Technologies -3,249.99%-278.24%-140.54% Does the media refer more to COLL or DBVT? In the previous week, DBV Technologies had 11 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 15 mentions for DBV Technologies and 4 mentions for Collegium Pharmaceutical. DBV Technologies' average media sentiment score of 0.89 beat Collegium Pharmaceutical's score of 0.86 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCollegium Pharmaceutical beats DBV Technologies on 10 of the 16 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$287.32M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-2.0921.3126.1919.90Price / Sales67.98278.47414.04113.66Price / CashN/A41.4736.1356.90Price / Book7.257.518.025.38Net Income-$113.92M-$55.05M$3.15B$248.50M7 Day Performance11.83%2.07%1.48%2.06%1 Month Performance29.72%4.84%3.67%4.86%1 Year Performance171.05%5.37%34.68%20.24% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.759 of 5 stars$10.30-1.8%$14.75+43.2%+170.1%$287.32M$4.15M-2.0980Analyst RevisionGap DownCOLLCollegium Pharmaceutical4.0327 of 5 stars$29.57-1.2%$43.75+48.0%-4.8%$961.71M$631.45M24.24210AKBAAkebia Therapeutics4.27 of 5 stars$3.64-0.3%$6.75+85.4%+278.1%$958.62M$160.18M-17.33430Insider TradeSYRESpyre Therapeutics1.9635 of 5 stars$14.97-1.6%$53.40+256.7%-34.8%$917.39M$890K-3.9773MLYSMineralys Therapeutics2.3188 of 5 stars$13.53-1.3%$32.25+138.4%+18.3%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.549 of 5 stars$8.85-3.8%$18.17+105.3%-36.6%$890M$169.12M-32.7870PHVSPharvaris1.4764 of 5 stars$17.60+3.5%$36.20+105.7%+5.8%$888.93MN/A-5.8530NRIXNurix Therapeutics1.227 of 5 stars$11.39-2.1%$30.18+164.9%-34.3%$887.38M$54.55M-4.07300News CoverageUpcoming EarningsAnalyst RevisionARDXArdelyx4.3597 of 5 stars$3.92+6.2%$10.89+177.8%-20.6%$882.85M$333.61M-17.8290ORICOric Pharmaceuticals4.2282 of 5 stars$10.15-1.6%$19.17+88.8%+41.6%$878.66MN/A-5.4380PRAXPraxis Precision Medicines3.2703 of 5 stars$42.05-2.2%$109.90+161.4%+18.0%$875.87M$8.55M-3.92110News Coverage Related Companies and Tools Related Companies Collegium Pharmaceutical Alternatives Akebia Therapeutics Alternatives Spyre Therapeutics Alternatives Mineralys Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Ardelyx Alternatives Oric Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
